Thank you for posting the above
@Sector, as well as the latest Tim Boreham article.
We were late getting a COVID-19 trial approved and therefore missed what turned out to be a massive opportunity. However, the trial has been approved and according to RMD's comments, "another option is to expand the program to other illnesses: Ards is common to influenza, pneumonia and even inhaling toxic fumes [...]." I agree, that this is financially a better option than to "chase the pandemic around the world."
Not every ARDS patient that gets admitted to ICU would automatically be eligible to participate in our trial either. And our trial is not the only trial. Therefore, even with the number of ICU patients increasing in AU, we may still not be able to recruit 24 patients (not only 12 as mentioned on here before).
A lot of COVID-19 trials had to be abandoned due to a lack of eligible patients (Google search, depending on the criteria to participate).
The latest research at Monash however, "Evaluating the therapeutic effects of Cynata-MSCs in a murine model of pulmonary fibrosis" may find us in a position - if proven to be successful of course - to be on the front foot for the next stage of COVID-19.
STARTEXCLUSIVE: Thousands of Covid-19 survivors who suffered lung damage are a ticking time bomb and face a death rate far worse than many cancers, top pulmonary doctor warnshttps://www.dailymail.co.uk/news/article-8463549/Top-medical-expert-warns-thousands-Americans-survived-COVID-19-ticking-time-bomb.html- Dr. Sassan Rafi says that COVID-19 patients diagnosed with pulmonary fibrosis after weeks on a ventilator face a shocking morbidity rate
- Pulmonary fibrosis is a lung disease that occurs when lung tissue is damaged and scarred and is caused by aggressive viruses like COVID-19
- Dr. Rafi has been studying lung disease for 15 years and says thousands of Americans hospitalized are at risk even after they recover from coronavirus
- [...]
- 'It's not just about who is dying acutely from the virus, it's about what's going to come years and years from now, once the virus has gone,' Dr. Rafi said
By RYAN PARRY, WEST COAST EDITOR FOR DAILYMAIL.COM
PUBLISHED: 03:12 AEST, 8 July 2020 | UPDATED: 17:13 AEST, 8 July 2020
[...]
The research scientist says that those diagnosed with pulmonary fibrosis after weeks on a ventilator face a shocking morbidity rate far worse than many cancers.
[...]
Pulmonary fibrosis is a lung disease that occurs when lung tissue is damaged and scarred and is caused by aggressive viruses like COVID-19.
This thickened, stiff tissue makes it more difficult for your lungs to work properly and exchange oxygen and can lead to respiratory failure.
Dr. Rafi, an anesthesiologist and founding Chief Medical Officer of Upright Pharmaceuticals, Inc, says that many hospitalized patients, even if they appear to make a full recovery from COVID-19 related illness, could still die due to fibrosis.
'Pulmonary fibrosis has a prognosis of three years, which is worse than many cancers, and currently there is no optimal treatment,' he explains.
Dr. Rafi says that even if a patient survives hospitalization and survives having fluid in their lungs for so many weeks, that can still lead to lingering effects such as fibrosis.
'So what we do is we scan the lungs and if we see fibrosis in the lungs that tells us that their lives may not come back. That's the point of no return,' he said.
'It's a progressive disease, meaning you may be feeling okay, but the fibrosis keeps getting worse and worse and that's one area, no one is addressing.'
The doctor says some patients may have to be dependent on a ventilator for the rest of their lives, while others may need a lung transplant.
[...]
ENDAlso see:
"Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy""The burden of fibrotic lung disease following SARS-CoV-2 infection is likely to be high; therefore, given the scale of the pandemic, the global burden of fibrotic lung disease will probably increase considerably."
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30225-3/fulltext"Pulmonary fibrosis secondary to COVID-19: a call to arms?"“Available data indicate that about 40% of patients with COVID-19 develop ARDS, and 20% of ARDS cases are severe.9 Of note, the average age of patients hospitalised with severe COVID-19 appears to be older than that seen with MERS or SARS, which is perhaps a consequence of wider community spread. In inflammatory lung disorders, such as those associated with autoimmune disease, advancing age is a risk factor for the development of pulmonary fibrosis. Given these observations, the burden of pulmonary fibrosis after COVID-19 recovery could be substantial.”
“At present, the long-term pulmonary consequences of COVID-19 remains speculative and should not be assumed without appropriate prospective study. Nonetheless, given the huge numbers of individuals affected by COVID-19, even rare complications will have major health effects at the population level. It is important that plans are made now to rapidly identify whether the development of pulmonary fibrosis occurs in the survivor population.”
“Coronavirus can cause lasting lung damage – but the effects may ease over time”
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228737/"Coronavirus can cause lasting lung damage – but the effects may ease over time"“The body replaces cells damaged by the virus with scar tissue, which is thick and stiff. This can result in a condition called 'pulmonary fibrosis', which has been seen in people with COVID-19 and is probably more likely to develop if the lungs are severely affected by the infection. The condition can make people breathless doing activities that they would usually manage without difficulty. Drugs that reduce scarring may have a role in preventing it."
"We don’t yet know what the impact of pulmonary fibrosis is after infection, but it may lead to long-term symptoms and a progressive fall in lung function. That’s why it’s important to watch out for the condition in people who suffer from severe COVID-19.”
https://theconversation.com/coronavirus-can-cause-lasting-lung-damage-but-the-effects-may-ease-over-time-140398A very relevant pre-clinical research project, due to finish end of September and therefore at a time when we might see the next phase of COVID-19.
The part that makes me very optimistic, which was also discovered at Monash (I have highlighted a few words):
"The study, published in the FASEB Journal, found that the MSCs could
effectively reduce inflammation, reversed signs of airway remodelling and completely normalised airway/lung fibrosis and airway hyperresponsiveness, particularly when delivered intranasally."
'"Most importantly, what we found was
you can treat fibrosis (hardening or scarring of the lung) very effectively,' said Associate Professor Samuel, who heads the Monash BDI's Fibrosis Laboratory."
https://medicalxpress.com/news/2017-06-trials-unique-stem-cells-potential.htmlAnother recent (dated 8th July 2020) write-up:
STARTRat's Ranthttps://mailchi.mp/everblucapital.com/rats-rant-the-wall-street-journaledition[...]
Today I caught up withDr RossA Macdonald who is theManaging Directorand Chief Executive Officerfor a bio tech company calledCynata Therapeutics Limited (CYP.asx)which is company who focus on clinical-stage stem cell and regenerative medicine andare about to go into phase 3 clinical trials for their treatment of osteoarthritis.
This news does not seem to have captured the investor attention that I think it deserves.
Starting a Phase 3 clinical trial is a pretty big deal for any biotech or pharmaceutical company as it is the last stage of clinical trial before seeking approval to market the product.
Even an aspiring Dr like me can tell you that much........
Osteoarthritis is something nearly everyone over 50 year old understands (and usually suffers from) so this trial could well interest some of you who read this especially that old bloke George who I spoke about above.
Although I’m not there yet, there are some days after a long fishing trip I feel like I have hit 69 already.
|
|
 | That may or may not be my mate George who I mentioned above.....
Nice catch, nice Mo & less lunch big fella !!!
|
|
The aim of the Phase 3 clinical trial is to assess the effect of Cymerus MSCs compared to placebo on clinical outcomes and knee joint structure over a two-year period, in 440 patients with osteoarthritis of the knee.
Pre clinical research has shown that MSCs can exert a number of important effects that may improve outcomes in patients with osteoarthritis, including reduced inflammation, promotion of tissue repair, new blood vessel formation, and regeneration of compromised cartilage.
CYP has also recently welcomed Darryl Maher to their Board: he has been instrumental in building CSL to the #1 company in Australia as you would have read on Monday and I presume he sees the opportunity in the next gen of bio pharmaceuticals, i.e. cell therapy.
|
|
I haven't met the great Dr yet but Ross the CEO has assured me that when things return to normal we can sit down one day and have a civilised lunch together and maybe we could all learn a thing or two from each other.
I'll teach the Dr how to fish !!!
Dr Maher adds global bio pharmaceutical development and commercialisation capability to the Cynata board, with over 23 years’ experience with CSL Limited.
CSL is one of the world’s most successful developers of biologic pharmaceutical products and has a market capitalisation of ~A$130 billion and has changed the lives of many including some bloke that plays the pokies downstairs that inherited CSL shares.
He has probably got enough loot to play the slappers for the rest of his life and that's a true story, ask the Tri Ads but anyway off topic now.
Dr Maher has had a long and successful career in pharmaceutical product development, most recently as the former Vice President of R&D and Medical Affairs at CSL Behring Australia where he was responsible for the development of multiple successful drug products from initiation through clinical development and ultimately to commercialisation.
Cynata Therapeutics Chairman, Dr Paul Wotton, said,
“Cynata continues to build a leading team with the addition of Dr Maher. With our rich and diverse Phase 2 product pipeline progressing, Darryl’s experience in global biopharmaceutical development and commercialisation will be a valuable addition.
We welcome Darryl to the Board and look forward to his contributions toward the advancement of Cynata and the Cymerus product pipeline"
|
|
Keep it on the watch list as there will be fireworks one way or another very soon and I hope for Ross, Paul, Doyles Fish, Kelso's Doors & Dr Maher the results are what we want and the product goes on the shelves.......real soon !!!
Ahhhhh the bio tech dream, don't let the gold diggers steal all the limelight boys !!! |
|
[...]
Nick KelsoWealth Advisor | EverBlu Capital[...]
END
(20min delay)
